Skip to main content

Peer Review reports

From: Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population

Original Submission
19 Dec 2023 Submitted Original manuscript
28 Dec 2023 Reviewed Reviewer Report - Michel Lanteri-Minet
7 Jan 2024 Reviewed Reviewer Report
20 Jan 2024 Author responded Author comments - Patricia Pozo-Roisch
23 Jan 2024 Reviewed Reviewer Report - Michel Lanteri-Minet
27 Jan 2024 Reviewed Reviewer Report
Resubmission - Version 2
20 Jan 2024 Submitted Manuscript version 2
Publishing
28 Jan 2024 Editorially accepted
12 Feb 2024 Article published 10.1186/s10194-024-01727-0

You can find further information about peer review here.

Back to article page